{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:08:25Z","timestamp":1786993705486,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.leukres.2025.107690","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T03:01:54Z","timestamp":1743735714000},"page":"107690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Safety, tolerability, and pharmacokinetics of ASP1235 in relapsed or refractory acute myeloid leukemia: A phase 1 study"],"prefix":"10.1016","volume":"152","author":[{"given":"Monzr M.","family":"Al Malki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Minden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Shima","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2512-1661","authenticated-orcid":false,"given":"Jason E.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley C.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Fredericks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5848-6221","authenticated-orcid":false,"given":"Amir T.","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1041-7689","authenticated-orcid":false,"given":"Maher","family":"Abdul-Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.leukres.2025.107690_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/jcm5030033","article-title":"Acute myeloid leukemia: a concise review","volume":"5","author":"Saultz","year":"2016","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.leukres.2025.107690_bib2","unstructured":"American Cancer Society, Acute myeloid leukemia, 2018. \u3008https:\/\/www.cancer.org\/content\/dam\/CRC\/PDF\/Public\/8674.00.pdf\u3009. (Accessed June 28, 2024)."},{"key":"10.1016\/j.leukres.2025.107690_bib3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.critrevonc.2018.11.010","article-title":"Clinical implications of measurable residual disease in AML: review of current evidence","volume":"133","author":"Moors","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2025.107690_bib4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-020-00992-1","article-title":"Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia","volume":"13","author":"Gebru","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2025.107690_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000914","article-title":"An overview of targeted therapies in acute myeloid leukemia","volume":"7","author":"Turkalj","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.leukres.2025.107690_bib6","unstructured":"RYDAPT (midostaurin) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2023."},{"key":"10.1016\/j.leukres.2025.107690_bib7","unstructured":"XOSPATA (gilteritinib) [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2023."},{"key":"10.1016\/j.leukres.2025.107690_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.612880","article-title":"FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies","volume":"10","author":"Kennedy","year":"2020","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2025.107690_bib9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"issue":"10","key":"10.1016\/j.leukres.2025.107690_bib10","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.3390\/molecules26102943","article-title":"Antibody-drug conjugates\u2014a tutorial review","volume":"26","author":"Baah","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.leukres.2025.107690_bib11","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.18632\/oncotarget.28331","article-title":"Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model","volume":"13","author":"Tsuzuki","year":"2022","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2025.107690_bib12","unstructured":"Astellas Pharma Inc., A study to evaluate escalating doses of ASP1235 (AGS62P1) given as monotherapy in subjects with acute myeloid leukemia (AML). ClinicalTrials.gov identifier: NCT02864290. \u3008https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02864290\u3009. (Accessed June 28, 2024)."},{"issue":"24","key":"10.1016\/j.leukres.2025.107690_bib13","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.leukres.2025.107690_bib14","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.2021015246","article-title":"Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML","volume":"141","author":"Roas","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2025.107690_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003882","article-title":"A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL","volume":"10","author":"Mehta","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2025.107690_bib16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-142709","article-title":"FLT3-CD3 bispecific antibody specifically eliminates normal hematopoietic progenitors and AML in humanized mouse models","volume":"136","author":"Sirochinsky","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2025.107690_bib17","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ymthe.2019.12.014","article-title":"An optimized full-length FLT3\/CD3 bispecific antibody demonstrates potent anti-leukemia activity and reversible hematological toxicity","volume":"28","author":"Yeung","year":"2020","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.leukres.2025.107690_bib18","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.3390\/biomedicines10102441","article-title":"Recent advances in the development of Anti-FLT3 CAR T-cell therapies for treatment of AML","volume":"10","author":"Pedersen","year":"2022","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.leukres.2025.107690_bib19","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2025.107690_bib20","unstructured":"MYLOTARG (gemtuzumab ozogamicin) [package insert]. Collegeville, PA: Wyeth Pharmaceuticals LLC; 2021."},{"issue":"4","key":"10.1016\/j.leukres.2025.107690_bib21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood-2017-06-789800","article-title":"A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2025.107690_bib22","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2019-128648","article-title":"Clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC), in patients with relapsed\/refractory (R\/R) acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"134","author":"Daver","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107690_bib23","unstructured":"ASH Clinical News, Phase III trials of vadastuximab talirine discontinued among safety concerns. \u3008https:\/\/ashpublications.org\/ashclinicalnews\/news\/3240\/Phase-III-Trials-of-Vadastuximab-Talirine\u3009. (Accessed June 28, 2024)."},{"key":"10.1016\/j.leukres.2025.107690_bib24","unstructured":"Debiopharm. Naratuximab emtansine (Debio 1562). \u3008https:\/\/www.debiopharm.com\/pipeline\/debio-1562m\/\u3009. (Accessed June 28, 2024)."},{"issue":"9","key":"10.1016\/j.leukres.2025.107690_bib25","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.neo.2017.06.001","article-title":"The antitumor activity of IMGN529, a CD37-targeting antibody-drug conjugate, is potentiated by rituximab in non-Hodgkin lymphoma models","volume":"19","author":"Hicks","year":"2017","journal-title":"Neoplasia"},{"issue":"7","key":"10.1016\/j.leukres.2025.107690_bib26","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1158\/1535-7163.MCT-15-0067","article-title":"AGS67E, an anti-CD37 monomethyl auristatin E antibody-drug conjugate as a potential therapeutic for B\/T-cell malignancies and AML: a new role for CD37 in AML","volume":"14","author":"Pereira","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.leukres.2025.107690_bib27","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody-drug conjugates in human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J. Ocul. Pharm. Ther."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T09:34:42Z","timestamp":1744882482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625000505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":27,"alternative-id":["S0145212625000505"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107690","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, tolerability, and pharmacokinetics of ASP1235 in relapsed or refractory acute myeloid leukemia: A phase 1 study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107690","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107690"}}